Apotex’s 180-Day Exclusivity for Generic Sitagliptin Threatens Merck’s Diabetes Sales
MRK•Apotex launched AB-rated generic sitagliptin tablets (25 mg/50 mg/100 mg) and 50 mg/500 mg and 50 mg/1000 mg sitagliptin-metformin combination, both qualifying for 180-day shared exclusivity in the US. This entry directly challenges Merck’s revenue from its branded Januvia and Janumet diabetes franchises.
1. Apotex Introduces Generic Sitagliptin Products
Apotex launched AB-rated sitagliptin tablets in 25 mg, 50 mg and 100 mg strengths, and fixed-dose sitagliptin-metformin tablets in 50 mg/500 mg and 50 mg/1000 mg strengths, all packaged in 30- and 90-count bottles. Both products qualify for a 180-day shared exclusivity period upon U.S. launch.
2. Merck’s Blockbuster Diabetes Franchise at Risk
Merck’s branded Januvia and Janumet combined generate multi-billion dollar annual sales by improving glycemic control in adults with type 2 diabetes. Entry of Apotex’s generics is expected to capture a substantial share of prescriptions, eroding Merck’s market position and revenue.
3. 180-Day Exclusivity Advantage
As first-to-file generics, Apotex’s products gain a temporary monopoly for 180 days, allowing them to establish pricing and distribution relationships before additional generic competitors enter the market.
4. Broader Market Implications
Over 30 million U.S. adults live with type 2 diabetes, driving high prescription volumes and payer scrutiny. Introduction of generics could lower treatment costs for payers and patients but pressure Merck’s margins and reshape competitive dynamics in the antidiabetic segment.
